Shilajit Benefits for Women: Bone, Skin & Energy (2026)

The bone-density trial that rewrote the shilajit narrative

For over a decade, shilajit marketing funneled straight toward men. Testosterone. Fertility. Gym performance. Then Usha Pingali, MD, a clinical pharmacologist at Nizam's Institute of Medical Sciences in Hyderabad, India, ran a trial that quietly redirected the entire evidence base.

The setup: sixty postmenopausal women aged 45–65 with osteopenia (the clinical stage of bone thinning that precedes osteoporosis) were randomized into three groups. Placebo. 250 mg of purified shilajit extract per day. Or 500 mg per day. The trial ran for 48 weeks, making it the longest shilajit supplementation study in any population, male or female. (PMID: 35933897)

The results were unambiguous. Women receiving placebo showed progressive bone loss at both the lumbar spine and femoral neck, exactly what you'd expect in the years following menopause when estrogen withdrawal accelerates bone turnover. Both shilajit groups preserved bone mineral density in a dose-dependent pattern: 250 mg slowed the loss, 500 mg essentially halted it.

Marker	Placebo	250 mg/day	500 mg/day
Lumbar spine BMD	↓ progressive loss	↑ preserved	↑↑ significantly preserved
Femoral neck BMD	↓ progressive loss	↑ preserved	↑↑ significantly preserved
CTX-1 (bone breakdown marker)	No change	↓ decreased	↓↓ decreased
RANKL/OPG ratio (bone resorption signaling)	Elevated	↓ improved	↓↓ significantly improved
hsCRP (inflammation)	No change	↓ decreased (p<0.001)	↓↓ decreased (p<0.001)
MDA (oxidative stress)	No change	↓ decreased	↓↓ decreased
GSH (antioxidant defense)	No change	↑ increased (p<0.001)	↑↑ increased (p<0.001)

What makes this trial stand out isn't just the BMD data. The researchers measured why bone was being preserved by tracking four separate mechanistic pathways simultaneously: bone turnover (CTX-1 and BALP), bone resorption signaling (RANKL/OPG ratio), systemic inflammation (hsCRP), and oxidative stress (MDA and GSH). Every pathway moved in the beneficial direction in a dose-dependent pattern. That kind of multi-marker consistency is rare in supplement research.

Eric Rawson, PhD, a professor of exercise science at Bloomsburg University who has published extensively on supplement efficacy, has noted in interviews that the shilajit-bone research represents one of the few supplement trials where the mechanistic data aligns cleanly with the clinical endpoint, making replication a priority rather than an afterthought.

Collagen, skin aging, and the transcriptome evidence

Skin aging isn't cosmetic vanity. It's a measurable biological process driven by declining collagen synthesis, reduced microvascular density, and cumulative oxidative damage. After menopause, collagen loss accelerates at roughly 2% per year for the first five years, according to dermatology research published by Ronald Moy, MD, past president of the American Academy of Dermatology.

In 2019, Amitava Das, PhD, and colleagues at Indiana University's Center for Regenerative Medicine and Engineering ran a transcriptome analysis on middle-aged women supplemented with shilajit. The study didn't measure wrinkle depth or skin hydration. It measured something arguably more foundational: which genes got turned on and off. (PMID: 31161927)

The findings showed upregulation of genes involved in two critical pathways. First, extracellular matrix (ECM) production, the biological machinery responsible for collagen and elastin synthesis. Second, microvascular function: the small blood vessels that supply nutrients and oxygen to the skin's deeper layers. When these pathways decline, skin loses firmness, elasticity, and that underlying "glow" that has nothing to do with surface-level moisturizing.

A critical caveat: this was gene-expression profiling, not a clinical outcome trial. Upregulated genes don't automatically translate to visible improvements you'd notice in a mirror. The study shows that the molecular infrastructure capable of producing collagen is being activated. Whether that activation reaches a clinically meaningful threshold over months or years hasn't been tested. Think of it as the biological plumbing being turned on, without yet measuring how much water flows through.

Still, the ECM connection is interesting because it dovetails with separate findings from Neltner et al. (2024), who showed that shilajit supplementation in active adults increased serum procollagen type I amino-terminal propeptide (Pro-C1α1). A direct marker of collagen synthesis. That study used a mixed-gender population, but collagen biology doesn't differ fundamentally between sexes. (PMID: 36791400)

Sexual function: the first women-only trial (Mosavi 2023)

Before 2023, every shilajit study on sexual health focused exclusively on men: testosterone levels, sperm count, libido. Women's sexual function was a blank space in the evidence base. Sadiqa Mosavi and colleagues at Tehran University of Medical Sciences filled part of that gap with a triple-blind RCT published in Traditional Medicine Research.

The trial enrolled 50 reproductive-aged women with self-reported sexual concerns. They were randomized to receive either 200 mg of shilajit tablets twice daily or placebo for 60 days, with follow-up measurements at 30, 60, and 90 days. The primary outcome was the Female Sexual Function Index (FSFI), a validated 19-item questionnaire covering six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain.

Forty-three women completed the study. The intervention group's mean FSFI score rose from 23.02 at baseline to 28.93 at day 90. The placebo group sat at 22.09. A total FSFI score above 26.55 is generally considered the clinical cutoff for normal sexual function, meaning the shilajit group crossed from below-threshold into normal range, while the placebo group didn't budge.

Improvements appeared across most individual domains, though the study didn't measure hormone levels (estrogen, progesterone, or testosterone) so the mechanism remains unknown. It could be direct hormonal modulation. It could be improved blood flow via nitric oxide pathways: fulvic acid has shown vasodilatory properties in animal models. Or it could be secondary to reduced fatigue and improved energy. The honest answer: we don't know yet.

The main limitation is sample size. Forty-three completers in a sexual-function trial barely scrapes past the statistical threshold for meaningful subgroup analysis. This needs replication in a larger cohort (ideally with hormonal panels) before anyone should consider the finding strong.

Energy, fatigue, and mitochondrial function in women

The fatigue question is where most women's interest in shilajit actually starts. Not bone density, not collagen, just feeling less drained by 2 PM.

The mechanistic story is straightforward. Shilajit's primary bioactive components (fulvic acid and dibenzo-α-pyrones (DBPs)) act on mitochondria, the organelles inside every cell that produce adenosine triphosphate (ATP), the body's energy currency. Carrasco-Gallardo and colleagues (2012), in a review of shilajit's phytocomplex published in the International Journal of Alzheimer's Disease, described how fulvic acid and dibenzo-α-pyrones support mitochondrial function, the cellular machinery that produces energy more efficiently. (PMID: 19444606)

The clinical evidence, however, is still limited for women specifically. The Keller 2019 study at the University of Nebraska-Lincoln tested 500 mg/day of PrimaVie shilajit in recreationally active adults for 8 weeks. The primary finding: shilajit preserved muscular strength during fatiguing exercise and raised serum hydroxyproline levels (a collagen breakdown marker that paradoxically signals active connective-tissue remodeling). That study included both men and women, but wasn't powered to detect sex-specific differences. (PMID: 30728074)

A 2026 pilot study in Cureus reported a roughly 32% drop in fatigue scores and a 25% reduction in C-reactive protein in healthy adults taking 500 mg/day for 28 days. Encouraging, but it was open-label, small, and without a placebo group, so treat it as hypothesis-generating rather than conclusive.

A 2024 systematic review pooled available shilajit trials and found consistent signals of reduced fatigue and improved stress resilience across studies, though the review noted that most individual trials had small sample sizes and short durations. The honest picture: the mechanistic evidence is solid, the clinical signals point in the right direction, and a definitive women-specific fatigue trial hasn't been done.

Iron status and mineral absorption

Iron-deficiency anemia affects roughly 10% of premenopausal women in the US, according to CDC surveillance data: primarily because menstruation creates a monthly iron deficit that diet alone doesn't always cover. Shilajit contains over 40 trace minerals, including iron, and its high fulvic acid content may enhance mineral absorption through chelation, essentially wrapping mineral molecules in a form that's easier for intestinal cells to absorb.

The preclinical evidence is suggestive. An animal study induced anemia in rats, then administered 500 mg/kg of shilajit for 11 days. The shilajit group showed significant increases in hemoglobin, red blood cell count, and hematocrit compared to untreated anemic controls. (PMID: 23580100)

In humans, this hasn't been tested directly. No RCT has examined shilajit supplementation for iron-deficiency anemia in women. The theoretical pathway (fulvic acid improving iron bioavailability) is plausible but unproven at the clinical level. If you have diagnosed iron deficiency, iron supplementation under medical supervision is the evidence-based approach. Shilajit should not be considered a replacement.

One important nuance: the mineral content of shilajit varies significantly by source region and purification method. Himalayan shilajit typically contains different mineral profiles than Russian mumijo or Andean shilajit. Unless a product provides a certificate of analysis showing its specific mineral content, you're guessing about what you're actually getting.

Worth noting: a 2024 systematic review in the Journal of Pharmaceutical Technology and Care Practice evaluated the overall safety and efficacy profile of shilajit across available clinical trials. The reviewers found consistent signals of anti-inflammatory and antioxidant activity, with no serious adverse events reported in any trial lasting up to 48 weeks. They also highlighted the need for larger, multi-center trials (particularly in women and in populations outside South Asia) to strengthen the generalizability of existing findings. The review classified shilajit as "generally well-tolerated with a favorable preliminary safety profile," while explicitly noting that long-term data beyond one year remains absent.

Can women take shilajit? Separating marketing from evidence

The short answer: yes, and the irony is that the strongest single clinical trial for shilajit in any population is a women-only study.

The marketing skew toward men happened for a historical reason, not a biological one. The earliest modern shilajit research focused on testosterone (Pandit et al., 2016 at Uttaranchal Ayurvedic College) and male fertility (Biswas et al., 2010). Those studies generated the "male vitality" branding that stuck. But shilajit's primary active components (fulvic acid, humic acid, and trace minerals) don't have sex-specific mechanisms. They act on mitochondria, collagen synthesis, and mineral metabolism, processes that operate identically in men and women. (PMID: 26395129)

The Pingali bone trial (women only, 48 weeks), the Mosavi sexual function trial (women only, 90 days), and the Das transcriptome study (women only) collectively represent more participant-days of women-specific data than exist for many supplements that actively market to women. The evidence gap isn't whether women can take shilajit. It's whether the broader supplement industry will update its positioning to reflect what the research actually shows.

Barbara Ehrlich, PhD, Professor of Pharmacology at Yale University, has noted in her work on mineral supplementation that the tendency to gender supplements based on early marketing rather than mechanism of action often delays women's access to compounds with genuine utility: a pattern clearly visible in shilajit's commercial history.

How to use shilajit: dosage, timing, and form

The clinical trial doses cluster tightly. Pingali used 250 mg and 500 mg daily. Mosavi used 200 mg twice daily (400 mg total). Keller used 250 mg twice daily (500 mg total). The converging range: 250–500 mg per day of a purified, standardized extract.

Timing hasn't been rigorously tested. Most trials dosed with meals, which makes physiological sense: fulvic acid's chelation activity may synergize with dietary mineral intake. Morning dosing is common in practice, since shilajit supports energy metabolism and some users report mild alertness, but no RCT has compared morning vs. evening administration.

Form matters more than most buyers realize. Shilajit comes as resin, capsules, powder, and now gummies. Resin is the traditional format (a sticky, tar-like substance dissolved in warm water or milk) and some practitioners argue it preserves the full spectrum of bioactive compounds. Capsules offer standardized dosing and convenience, which is why all three women-specific clinical trials used capsule or tablet forms. Gummies almost universally contain lower doses and added sugars, making them the weakest option for anyone trying to match clinical trial protocols.

Our Shilajit Adaptogen Complex delivers a standardized dose per serving. Start at the lower end of the clinical range and assess tolerance over 2–4 weeks before increasing. For detailed dosing protocols and cycling guidance, see our shilajit dosage guide.

A practical point on cycling: long-term continuous-use data beyond 48 weeks doesn't exist. Many practitioners recommend a 90-days-on, 2-to-4-weeks-off cycle as a precautionary approach. This isn't because of documented safety concerns. It's because the absence of evidence isn't the same as evidence of absence.

Does shilajit help with weight management?

This is one of the most searched questions about shilajit for women, and the honest answer is: the direct evidence is thin.

No RCT has tested shilajit as a standalone weight-management intervention in women. The Martinez et al. 2025 trial, published in Nutrients, tested a combination supplement (shilajit plus chromium plus Phyllanthus emblica (amla)) in overweight adults (both sexes) undergoing exercise and caloric restriction. The combination group showed modest improvements in body composition, lipid profiles, and insulin sensitivity compared to placebo. But because three compounds were combined, you can't attribute any specific outcome to shilajit alone. (PMID: 39861186)

The theoretical pathway for weight influence runs through mitochondrial function (more efficient energy metabolism), inflammation reduction (chronic low-grade inflammation impairs metabolic signaling), and potential improvements in insulin sensitivity. These are real mechanisms, but "theoretical pathway" and "clinically proven for weight loss" are worlds apart.

If someone tells you shilajit will help you lose weight, they're outrunning the evidence. It may support the metabolic infrastructure that makes a healthy diet and exercise program slightly more effective, but calling it a weight-management supplement would be irresponsible given the current data.

Shilajit vs. ashwagandha: which adaptogen for women?

Women frequently compare these two because they occupy similar "adaptogen" shelf space. The evidence profiles are quite different.

Ashwagandha (KSM-66) has substantially more clinical data in women specifically. A 2012 RCT by Chandrasekhar et al. showed significant reductions in serum cortisol and perceived stress in adults (mixed gender). The Salve et al. 2019 trial tested KSM-66 specifically for sleep quality. And multiple trials have examined ashwagandha's effects on thyroid function, anxiety, and reproductive hormones in women. (PMID: 23439798)

Shilajit's women-specific edge is bone density, no ashwagandha trial has produced comparable BMD data. Shilajit also delivers trace minerals and fulvic acid, which ashwagandha doesn't contain.

The practical question isn't "which is better". It's "what are you trying to address?" For stress and cortisol management, ashwagandha has deeper evidence. For bone health and mineral support, shilajit has the stronger trial. For energy, both show signals but neither has a definitive women-specific fatigue trial. See our shilajit vs. ashwagandha comparison for a deeper breakdown, and our ashwagandha for women guide for the full evidence base.

Shilajit supplement comparison: what women should look for

The shilajit market is notoriously opaque. A 2025 analysis published in BMC Chemistry found that some commercial shilajit supplements contained thallium (a heavy metal more toxic than mercury) at levels above acceptable thresholds. This makes third-party testing non-negotiable, not optional.

Three specs separate clinical-grade shilajit from tar in a jar: fulvic acid content (target ≥50% by HPLC), dibenzo-α-pyrone (DBP) disclosure, and a current certificate of analysis showing ICP-MS heavy-metal testing for the specific batch you're buying, not a generic report from two years ago.

Brand	Form	Dose/Serving	Fulvic Acid	DBP Disclosed	3rd-Party Tested	~Price/Month
YourHealthier Shilajit Adaptogen Complex	Capsule	500 mg	Standardized	✓	✓	$24.99
Nootropics Depot PrimaVie	Capsule	250 mg	≥50%	✓	✓	$19–30
Double Wood Shilajit	Capsule	1,000 mg	20%	✗	✓	$20–25
Himalaya Shilajit	Capsule	250 mg	Not disclosed	✗	✓	$15–20
Supersmart Super Shilajit (PrimaVie)	Capsule	500 mg	50%	✓	✓	$25–35
Pure Himalayan (Resin)	Resin	~300–500 mg	Varies by batch	Varies	Varies	$30–60

Prices approximate as of mid-2026 and vary by retailer. Always verify COA availability before purchasing.

A note on resin vs. capsule for women specifically: the clinical trials that generated the strongest women-specific evidence (Pingali, Mosavi) both used capsule/tablet forms of standardized extract. If your goal is to replicate what the research tested, capsules are the format with evidence behind them. Resin may contain the full phytocomplex, but no women-specific RCT has used resin as the delivery vehicle.

How long does shilajit take to work for women?

The timeline depends entirely on what you're measuring. The Pingali bone-density trial didn't show statistically significant BMD changes until the 24-week mark, with effects strengthening through week 48. Bone remodeling is inherently slow. Osteoclasts break down old bone and osteoblasts build new matrix over cycles that take 4–6 months to complete. Anyone expecting bone-level results in a few weeks fundamentally misunderstands the biology.

The sexual-function improvements in the Mosavi trial appeared faster. FSFI scores showed measurable changes by day 30, with continued improvement through day 60 and 90. This faster timeline makes physiological sense: if the mechanism involves improved blood flow or reduced fatigue, those are weeks-scale adaptations rather than months-scale structural changes.

For subjective energy and fatigue, user reports (and the limited pilot data) suggest 2–4 weeks for noticeable differences. The mitochondrial mechanisms behind ATP production don't require structural remodeling. They involve upregulation of existing enzymatic pathways, which operates on a shorter timeline. Still, "noticeable" is subjective and heavily influenced by expectation bias. The smartest approach: commit to 8–12 weeks at a consistent dose before evaluating. Keep a brief journal of energy levels, sleep quality, and exercise recovery rather than relying on memory alone.

For a detailed timeline breakdown by benefit type, see our How Long Does Shilajit Take to Work? guide.

Stacking shilajit with other supplements

Shilajit's fulvic acid content creates an interesting synergy question. Because fulvic acid enhances mineral chelation and cellular transport, some researchers hypothesize it could amplify the absorption of co-administered supplements, particularly mineral-based ones like magnesium glycinate or iron.

In practice, the two most common stacks for women are shilajit plus ashwagandha (combining bone and mineral support with stress-cortisol management) and shilajit plus magnesium (addressing two of the most common mineral insufficiencies in women simultaneously). Neither combination has been tested in a dedicated RCT, but the individual mechanisms don't conflict, and since both ashwagandha and magnesium have strong standalone evidence in women, the theoretical risk of combining them with shilajit is low.

One caution: avoid stacking shilajit with high-dose iron supplements without physician guidance. The additive mineral load could push total iron intake above comfortable levels, particularly in women who aren't iron-deficient. Get your ferritin tested before combining. For curated evidence-based stack recommendations, see our best supplement stacks guide.

It is also worth setting expectations about what shilajit will not do. It is not a substitute for resistance training, adequate dietary protein, or vitamin D and calcium intake when bone health is the goal. The Pingali trial participants were not doing anything unusual beyond taking the supplement, but bone metabolism responds most strongly to a combination of mechanical loading, sufficient micronutrients, and time. Shilajit appears to add to that foundation rather than replace any part of it, which is the honest way to frame any single supplement in a broader health picture.

The counter-argument: what the skeptics get right

Robert Saper, MD, MPH, Chair of the Department of Wellness and Preventive Medicine at Cleveland Clinic, has been publicly cautious about shilajit supplements. His core argument: while the individual trial results are encouraging, the total evidence base is still thin: a handful of small trials, mostly from a single research group (Pingali's team), with limited independent replication. He recommends waiting for the science to mature before adopting shilajit as a routine supplement.

He's not wrong on the facts. The Pingali bone trial had 60 participants, solid for a pilot, small by pharmaceutical standards. The Mosavi sexual-function trial had 43 completers. The Das skin study was transcriptomic, not clinical. Compare this to, say, vitamin D for bone health, where the evidence base includes dozens of large-scale RCTs and multiple meta-analyses involving thousands of participants.

There's also the quality-control problem. Shilajit isn't a single standardized molecule like ascorbic acid. It's a complex phytocomplex whose composition varies by geographic origin, altitude, season of collection, and purification method. What Pingali tested using Natreon's PrimaVie extract may not be biochemically identical to what's in a jar of resin sourced from a different mountain range. This isn't a theoretical concern: the BMC Chemistry findings on thallium contamination demonstrate that "shilajit" is not a uniform product category.

Where the skeptics sometimes overreach is in dismissing the evidence entirely because it's small. Small-sample-size ≠ wrong. The Pingali trial's multi-marker consistency (every measured pathway moved in the expected direction) actually increases confidence beyond what the sample size alone would justify. The appropriate stance isn't dismissal. It's calibrated optimism paired with insistence on product quality verification.

Why YourHealthier

Our Shilajit Adaptogen Complex uses a standardized extract with documented fulvic acid content and third-party heavy-metal testing. We publish batch-specific certificates of analysis (not generic reports) because the contamination risks in the shilajit category make transparency non-optional. The capsule format matches what was used in the clinical trials that generated the strongest women-specific evidence. We don't claim shilajit will make you lose weight or reverse aging, because the data doesn't support those claims. We do think the bone-density and antioxidant evidence is real and worth paying attention to, particularly for postmenopausal women and active women looking for connective-tissue support. See the full product details and COA at our product page.

Shilajit side effects in women

Shilajit side effects in women are uncommon at the doses used in clinical trials, but they are worth knowing before you start. In the Pingali bone-density study, 250 to 500 mg per day for 48 weeks produced no significant adverse effects, which is a reassuring safety signal given the length of that trial. The issues that do come up are mostly tied to product quality and individual circumstances rather than shilajit itself.

The most reported mild effects are digestive: some women notice loose stools or stomach upset, usually when starting at a higher dose or using an unpurified product. Starting low and choosing a third-party-tested extract reduces this. A second consideration is the mineral and iron content, which is a benefit for most premenopausal women but a problem for anyone with iron-overload conditions. The most serious risks are not from shilajit itself but from contamination: unpurified resin from unverified sources has tested positive for heavy metals including lead and arsenic, which is why a current certificate of analysis is non-negotiable. The cautions below break down who should be most careful.

Who should be cautious

Pregnant and breastfeeding women: No clinical safety data exists for shilajit during pregnancy or lactation. The absence of adverse-event data isn't the same as demonstrated safety. Avoid use during these periods entirely.

Women with thyroid conditions: Shilajit contains iodine and other trace minerals that could theoretically interact with thyroid hormone levels. If you're taking levothyroxine or other thyroid medications, consult your endocrinologist before adding shilajit. No drug-interaction study has been conducted, so caution is warranted.

Iron-overload conditions: Hemochromatosis and other conditions involving elevated ferritin levels create a scenario where additional mineral intake (including the iron in shilajit) could exacerbate the problem. Check your iron panel with your physician before starting.

Women on hormone replacement therapy (HRT): The Mosavi trial suggested possible effects on sexual function, which could involve hormonal pathways. If you're already modulating hormones through HRT, adding a compound with unclear hormonal activity introduces unpredictable interactions. Discuss with your prescribing physician.

Women with kidney conditions: The mineral load in shilajit (particularly if taken alongside other mineral supplements) could stress compromised kidneys. Anyone with reduced kidney function should have their nephrologist weigh in.

Unverified products: This is less about who you are and more about what you're buying. Unpurified, untested shilajit from unverified sources carries real contamination risks (heavy metals including lead, mercury, arsenic, and thallium). If a product doesn't offer a current COA with ICP-MS testing, don't buy it regardless of your health status.

For a complete safety analysis, see our Is Shilajit Safe? What the Research Says.

Frequently asked questions

Related reading

• Shilajit Benefits: 8 Effects Ranked by Evidence
• Shilajit Benefits for Men: Testosterone, Fertility & Energy
• Shilajit Dosage: How Much Should You Take?
• Best Time to Take Shilajit: Morning, Night, or Before Workout?
• Is Shilajit Safe? What the Research Says
• How Long Does Shilajit Take to Work?
• Shilajit vs Ashwagandha: Which Adaptogen?
• Ashwagandha for Women: Benefits, Hormones & Safety
• Creatine for Women: Benefits & Safety
• Magnesium Glycinate Benefits
• Longevity Supplements: 7 That Actually Work
• Best Supplements for Stress
• Cortisol & Sleep
• Best Supplement Stacks: A No-Hype Guide
• Magnesium for Heart Health
• What Is Mushroom Coffee?

References

1. Pingali U, Nutalapati C. "Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial." Phytomedicine. 2022;105:154334. PubMed
2. Das A, et al. "Skin Transcriptome of Middle-Aged Women Supplemented With Natural Herbo-mineral Shilajit Shows Induction of Microvascular and Extracellular Matrix Mechanisms." Skin Pharmacol Physiol. 2019;32(4):228-236. PubMed
3. Mosavi S, Tabarrai M, Tansaz M, et al. "Effects of oral Shilajit tablets on sexual function and sexual quality of life among reproductive-aged women: a triple-blind randomized clinical trial." Traditional Medicine Research. 2023;8:66.
4. Keller JL, et al. "The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels." J Int Soc Sports Nutr. 2019;16(1):3. PubMed
5. Neltner TJ, et al. "Effects of 8 Weeks of Shilajit Supplementation on Serum Pro-c1α1." J Diet Suppl. 2024;21(2):237-250. PubMed
6. Carrasco-Gallardo C, Guzmán L, Maccioni RB. "Shilajit: a natural phytocomplex with potential procognitive activity." Int J Alzheimers Dis. 2012;2012:674142. PubMed
7. Pandit S, et al. "Clinical evaluation of purified Shilajit on testosterone levels in healthy volunteers." Andrologia. 2016;48(5):570-575. PubMed
8. Stohs SJ. "Safety and efficacy of shilajit (mumie, moomiyo)." Phytother Res. 2014;28(4):475-479. PubMed
9. Martinez V, et al. "Effects of 12 Weeks of Chromium, Phyllanthus emblica Fruit Extract, and Shilajit Supplementation on Markers of Cardiometabolic Health." Nutrients. 2025;17(3):475. PubMed
10. Chandrasekhar K, et al. "A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root." Indian J Psychol Med. 2012;34(3):255-262. PubMed